New insights into sickle cell disease: Mechanisms and investigational therapies

Current Opinion in Hematology

Volumn 23, Issue 3, 2016, Pages 224-232

  Kato, Gregory J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Hemolysis; Hydroxyurea; Inflammation; Sickle cell; Vasculopathy

Indexed keywords

HYDROXYUREA; NITRIC OXIDE;

BLOOD CELL; BRAIN INJURY; CELL ADHESION; CHRONIC PAIN; DISEASE SEVERITY; ENDOTHELIUM CELL; EXPERIMENTAL THERAPY; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; NOCICEPTION; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; VASCULAR DISEASE; ANEMIA, SICKLE CELL; METABOLISM;

ANEMIA, SICKLE CELL; HUMANS; HYDROXYUREA;

EID: 84963636078     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000241     Document Type: Review

References (55)

1. Lebensburger JD, Hilliard LM, Pair LE, et al. Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov. Clin Trials 2015; 12:575-583.
2. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033-1048.
3. Brown FC, Conway AJ, Cerruti L, et al. Activation of the erythroid K-Cl cotransporter Kcc1 enhances sickle cell disease pathology in a humanized mouse model. Blood 2015; 126:2863-2870.
4. Brugnara C, Bunn HF, Tosteson DC. Regulation of erythrocyte cation and water content in sickle cell anemia. Science 1986; 232:388-390.
5. Sun K, Zhang Y, Bogdanov MV, et al. Elevated adenosine signaling via adenosine A2B receptor induces normal and sickle erythrocyte sphingosine kinase 1 activity. Blood 2015; 125:1643-1652.
6. Funnell AP, Prontera P, Ottaviani V, et al. 2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. Blood 2015; 126:89-93.
7. Krivega I, Byrnes C, de Vasconcellos JF, et al. Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR/gammaglobin looping. Blood 2015; 126:665-672.
8. Renneville A, Van Galen P, Canver MC, et al. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood 2015; 126:1930-1939.
9. Cui S, Lim KC, Shi L, et al. The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. Blood 2015; 126:386-396.
10. Chou YC, Chen RL, Lai ZS, et al. Pharmacological induction of human fetal globin gene in hydroxyurea-resistant primary adult erythroid cells. Mol Cell Biol 2015; 35:2541-2553.
11. Boosalis MS, Sangerman JI, White GL, et al. Novel inducers of fetal globin identified through high throughput screening (HTS) are active in vivo in anemic baboons and transgenic mice. PLoS One 2015; 10:e0144660.
12. Das N, Xie L, Ramakrishnan SK, et al. Intestine-specific disruption of hypoxiainducible factor (HIF)-2alpha improves anemia in sickle cell disease. J Biol Chem 2015; 290:23523-23527.
13. Gladwin MT. Revisiting the hyperhemolysis paradigm. Blood 2015; 126:695-696.
14. Nguyen KL, Alam S, Tian X, et al. Elevated transpulmonary gradient and cardiac magnetic resonance-derived right ventricular remodeling predict poor outcomes in sickle cell disease. Haematologica 2016; 101:e40-e43.
15. Caughey MC, Poole C, Ataga KI, et al. Estimated pulmonary artery systolic pressure and sickle cell disease: a meta-analysis and systematic review. Br J Haematol 2015; 170:416-424.
16. Schimmel M, van Beers EJ, van Tuijn CF, et al. N-terminal pro-B-type natriuretic peptide, tricuspid jet flow velocity, and death in adults with sickle cell disease. Am J Hematol 2015; 90:E75-E76.
17. Detterich JA, Kato RM, Rabai M, et al. Chronic transfusion therapy improves but does not normalize systemic and pulmonary vasculopathy in sickle cell disease. Blood 2015; 126:703-710.
18. Almeida CB, Souza LE, Leonardo FC, et al. Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood 2015; 126:711-720.
19. Sparkenbaugh EM, Chantrathammachart P, Wang S, et al. Excess of heme induces tissue factor-dependent activation of coagulation in mice. Haematologica 2015; 100:308-314.
20. Camus SM, De Moraes JA, Bonnin P, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood 2015; 125:3805-3814.
21. Wood JC, Cohen AR, Pressel SL, et al. Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. Br J Haematol 2015; 172:122-130.
22. Saraf SL, Zhang X, Shah B, et al. Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy. Haematologica 2015; 100:1275-1284.
23. Schaer CA, Deuel JW, Schildknecht D, et al. Haptoglobin preserves vascular nitric oxide signaling during hemolysis. Am J Respir Crit Care Med 2015. [Epub ahead of print]
24. Vinchi F, Costa da Silva M, Ingoglia G, et al. Hemopexin therapy reverts hemeinduced pro-inflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease. Blood 2016; 127:473-486.
25. Deuel JW, Vallelian F, Schaer CA, et al. Different target specificities of haptoglobin and hemopexin define a sequential protection system against vascular hemoglobin toxicity. Free Radic Biol Med 2015; 89:931-943.
26. Bernaudin F, Verlhac S, Arnaud C, et al. Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood 2015; 125:1653-1661.
27. Kawadler JM, Kirkham FJ, Clayden JD, et al. White matter damage relates to oxygen saturation in children with sickle cell anemia without silent cerebral infarcts. Stroke 2015; 46:1793-1799.
28. Cancio MI, Helton KJ, Schreiber JE, et al. Silent cerebral infarcts in very young children with sickle cell anaemia are associated with a higher risk of stroke. Br J Haematol 2015; 171:120-129.
29. van der Land V, Hijmans CT, de Ruiter M, et al. Volume of white matter hyperintensities is an independent predictor of intelligence quotient and processing speed in children with sickle cell disease. Br J Haematol 2015; 168:553-556.
30. van der Land V, Mutsaerts HJ, Engelen M, et al. Risk factor analysis of cerebral white matter hyperintensities in children with sickle cell disease. Br J Haematol 2016; 172:274-284.
31. Novelli EM, Elizabeth Sarles C, Jay Aizenstein H, et al. Brain venular pattern by 7T MRI correlates with memory and haemoglobin in sickle cell anaemia. Psychiatry Res 2015; 233:18-22.
32. van der Land V, Zwanenburg JJ, Fijnvandraat K, et al. Cerebral lesions on 7 tesla MRI in patients with sickle cell anemia. Cerebrovasc Dis 2015; 39:181-189.
33. Alvarado AM, Ward KM, Muntz DS, et al. Heart rate recovery is impaired after maximal exercise testing in children with sickle cell anemia. J Pediatr 2015; 166:389-393.
34. Colombatti R, Ermani M, Rampazzo P, et al. Cognitive evoked potentials and neural networks are abnormal in children with sickle cell disease and not related to the degree of anaemia, pain and silent infarcts. Br J Haematol 2015; 169:597-600.
35. Darbari DS, Hampson JP, Ichesco E, et al. Frequency of hospitalizations for pain and association with altered brain network connectivity in sickle cell disease. J Pain 2015; 16:1077-1086.
36. Cataldo G, Rajput S, Gupta K, et al. Sensitization of nociceptive spinal neurons contributes to pain in a transgenic model of sickle cell disease. Pain 2015; 156:722-730.
37. Vincent L, Vang D, Nguyen J, et al. Cannabinoid receptor-specific mechanisms to ameliorate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation. Haematologica 2015. [Epub ahead of print]
38. Vang D, Paul JA, Nguyen J, et al. Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice. Haematologica 2015; 100:1517-1525.
39. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, noninferiority trial. Lancet 2015. [Epub ahead of print]
40. Hankins JS, McCarville MB, Rankine-Mullings A, et al. Prevention of conversion to abnormal tcd with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. Am J Hematol 2015; 90:1099-1105.
41. Bartolucci P, Habibi A, Stehle T, et al. Six months of hydroxyurea reduces albuminuria in patients with sickle cell disease. J Am Soc Nephrol 2015. [Epub ahead of print]
42. Lopes FC, Traina F, Almeida CB, et al. Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea. Haematologica 2015; 100:730-739.
43. Baird JH, Minniti CP, Lee JM, et al. Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide. Br J Haematol 2015; 168:737-746.
44. Eiymo MwaMpollo MS, Brandt EB, Shanmukhappa SK, et al. Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13. J Clin Invest 2016; 126:571-584.
45. van Beers EJ, Yang Y, Raghavachari N, et al. Iron, inflammation, and early death in adults with sickle cell disease. Circ Res 2015; 116:298-306.
46. Hounkpe BW, Fiusa MM, Colella MP, et al. Role of innate immunity-triggered pathways in the pathogenesis of sickle cell disease: a meta-analysis of gene expression studies. Sci Rep 2015; 5:17822.
47. Zhang D, Chen G, Manwani D, et al. Neutrophil ageing is regulated by the microbiome. Nature 2015; 525:528-532.
48. Telen MJ, Wun T, McCavit TL, et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood 2015; 125:2656-2664.
49. Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med 2015. [Epub ahead of print]
50. Manwani D, Chen G, Carullo V, et al. Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis. Am J Hematol 2015; 90:381-385.
51. Barazia A, Li J, Kim K, et al. Hydroxyurea with AKT2 inhibition decreases vasoocclusive events in sickle cell disease mice. Blood 2015; 126:2511-2517.
52. Jimenez MA, Tutuncuoglu E, Barge S, et al. Quantitative microfluidic fluorescence microscopy to study vaso-occlusion in sickle cell disease. Haematologica 2015; 100:e390-e393.
53. Picot J, Ndour PA, Lefevre SD, et al. A biomimetic microfluidic chip to study the circulation and mechanical retention of red blood cells in the spleen. Am J Hematol 2015; 90:339-345.
54. Peranteau WH, Hayashi S, Abdulmalik O, et al. Correction of murine hemoglobinopathies by prenatal tolerance induction and postnatal nonmyeloablative allogeneic BM transplants. Blood 2015; 126:1245-1254.
55. Hoban MD, Cost GJ, Mendel MC, et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood 2015; 125:2597-2604.